the international guidelines for the management of preterm labor, delaying delivery allows the administration of a complete course of antepartum glucocorticosteroids to the mother, to reduce the severity of idiopathic respiratory distress syndrome and to arrange in utero transfer to a center with neonatal intensive care facilities. [4] [5] [6] The current recommendation is a single course of glucocorticosteroids within 7 days to pregnant women at risk of preterm delivery between 24 and 34 weeks gestation. [5] [6] [7] Corticosteroids regulate the production of lung surfactant, which takes 4-7 days to become effective following initial corticosteroid administration. 8 This also reflects the need for an effective tocolytic drug to delay preterm delivery for at least 7 days, in order for the corticosteroid to be most effective.
A number of tocolytic agents are currently in use for the treatment of preterm labor, and have shown different efficacy and safety. Some are licensed for use (oxytocin receptor antagonist and ritodrine in selected countries), but most are not (nitric oxide donors, prostaglandin synthetase inhibitors, magnesium sulfate and calcium channel blockers and some beta-agonists). Only one group of drugs was developed specifically to treat spontaneous preterm labor (the oxytocin receptor antagonist atosiban), and the others were developed for other purposes. Unlike atosiban, most of the other tocolytics are not uterospecific, therefore, multi-organ fetomaternal side effects are expected. 1 Beta-agonists are often associated with maternal cardiovascular adverse events, and in the past, reports of pulmonary edema, cardiac arrhythmia and hypokalemia have been common. 9 Atosiban acts as a competitive antagonist of oxytocin to inhibit oxytocin-induced uterine contraction, and is the first oxytocin antagonist designed for specific treatment of preterm labor. 10 Currently, clinical studies of tocolytic treatment that targets Asian populations are scarce. The objective of this trial was to compare the tocolytic efficacy and safety profile of atosiban and ritodrine in the treatment of spontaneous preterm labor in Taiwanese women. This study was designed to monitor adverse events, with a particular focus on tachycardia, which is frequently associated with the conventional betaagonist therapy. This study will serve to provide further clinical data on Asian populations. Previously, racial variation has been reported as a contributor to different preterm frequency between ethnic groups. 11, 12 
Patients and Methods
This was a randomized, open label, controlled trial, carried out in the obstetric department at the Taiwan University Hospital, to compare the tocolytic efficacy and safety of atosiban and ritodrine in women diagnosed with spontaneous preterm labor between July 26, 2002 and July 15, 2005 . The study protocols and the written informed consent were approved by the ethics committees and approved by the Institutional Review Board of the National Taiwan University Hospital and the Taiwan Department of Health. Each woman reviewed and voluntarily signed the written consent form before enrolment.
A total of 45 patients were included in this study after fulfilling the following inclusion criteria: (1) regular uterine contractions (≥ 30 seconds in duration, at a rate of ≥ 4 times in 30 minutes), with cervical dilation of 0-3 cm and cervical effacement of ≥ 50%; (2) ≥ 18 years of age; and (3) gestational age of 24-33 weeks. Exclusion criteria were: high-order multiple pregnancy (more than twins); ruptured membranes; major vaginal bleeding (continuous vaginal bleeding with fresh blood or bleeding volume > 100 mL); pre-eclampsia or hypertension (blood pressure > 140/90 mmHg); fever > 37.5°C; urinary tract infection; fetal/ placental/amniotic abnormalities (e.g. major fetal anomalies, chorioamnionitis, polyhydramnios, fetal growth restriction or placenta previa); serious maternal disease (e.g. cardiovascular disease, hyperthyroidism, diabetes, pheochromocytoma or asthma); any contraindication to the use of beta-agonists; alcohol or drug abuse; previous exposure to nonsteroidal anti-inflammatory drugs for tocolysis within 12 hours of study entry; history of hypersensitivity to any component of the study drugs and participation in a clinical trial within 1 month.
Women were computer-randomized into two groups to ensure that the two treatments were equally distributed between the gestational age subgroups. The investigational drug atosiban (Tractocile ® ) was supplied by Ferring AB (Limhamn, Sweden) and ritodrine (Yutopar ® ) was supplied by Solvay (Taipei, Taiwan). Women who were randomized to receive atosiban were given a single intravenous (i.v.) bolus dose (6.75 mg in 0.9 mL normal saline) followed by a loading i.v. infusion at 18 mg/hour (300 μg/minute) for 3 hours, and a subsequent i.v. infusion at 6 mg/ hour (100 μg/minute) for 15 hours. Ritodrine was given as an i.v. infusion at an initial rate of 20 mL/hour (66.6 μg/minute) and increased by 10 mL/hour (33.3 μg/minute) every 10-30 minutes, until the desirable uterine response (uterine quiescence or < 4 contractions per hour) was obtained. Both atosiban and ritodrine were administered to the patients for a maximum of 18 hours during the first treatment. Retreatment with the study drug was allowed if there was recurrence of preterm labor and if all eligibility criteria were still fulfilled by the patient.
The aim was to compare efficacy, safety and tolerability of atosiban and ritodrine at conventional doses in Taiwanese women. The primary endpoint was to compare the proportion of patients who did not deliver and did not receive alternative tocolytic therapy after 7 days of treatment, which was defined as tocolytic efficacy, a composite of efficacy and tolerability. Secondary endpoints included measurement of other efficacy parameters such as the proportion of patients who did not deliver after 2 days of treatment and did not require alternative tocolytic therapy. During the study, maternal, fetal and neonatal safety profiles were monitored. Other parameters such as the frequency of uterine contractions, gestational age at delivery, infant birth weight, number of maternal and fetal deaths, and early drug discontinuation with/without alternative tocolytic therapy were also recorded.
Women could discontinue the therapy treatment under the following circumstances: (1) occurrence of serious adverse events; (2) treatment failure; (3) rupture of membranes during the study; (4) significant protocol violation; (5) patient's request; and (6) development of an intercurrent illness that would put the patient at increased risk or invalidate the results of the study. Any occurrences of the above circumstances were documented.
Progression of labor, defined as initial treatment failure, was assumed when any two of the following three criteria were met: a contraction rate ≥ 4/hour; an increase in cervical dilation of ≥ 1 cm from the initial measurement; and an increase in cervical effacement of ≥ 25% from the initial measurement. Efficacy evaluation, including uterine contraction rate, cervical dilation and effacement, was performed at 1, 2, 6 and 12 hours and at the end of the drug treatment at 18 hours, and thereafter at 1 and 2 days until 7 days (primary endpoint), with or without the need for alternative tocolytic therapy. Retreatment with the same i.v. drug was allowed if the preterm labor recurred within 18 hours of initial therapy, and the inclusion criteria were still fulfilled.
Safety parameters such as maternal and fetal heart rate, and maternal blood pressure were recorded within the first 2 days after therapy initiation. The severity and type of adverse events were assessed throughout the entire study period. The patients were asked to classify the reported adverse events according to a severity scale of mild, moderate or severe. The causal relationship between the treatment drug and adverse events was also documented and rated as probable, possible or unlikely. Special attention was paid to the occurrence of maternal tachycardia (heart rate > 120 bpm). Also, signs of palpitation, dyspnea, hyperglycemia and vomiting were also recorded.
Routine laboratory parameters were recorded for all treated women at baseline and after the completion of the study. 
Statistical analysis
All statistical analyses were performed using SAS version 8.0 software (SAS Institute Inc., Cary, NC, USA). The intention-to-treat (ITT) population was the full analysis set in which all patients were randomized to receive at least one of the study drugs. The per-protocol (PP) population included patients from the ITT population who did not commit any protocol violations.
For evaluation of the primary endpoint, the two-sample χ 2 test with Yates' or Fisher's exact test was used to evaluate the tocolytic efficacy of the ITT population. All analyses were based on two-tail statistics, and a statistically significant value of p < 0.05 was sufficient for the rejection of the null hypothesis. The 95% confidence intervals (CI) for these primary endpoints were also established. Secondary endpoint analysis was conducted for the ITT population. Comparative analysis between the two treatment groups was performed by Student's t test or two-sample χ 2 test (or Fisher's exact test) for continuous and categorical data, respectively. The analyses were based on two-tail statistics, and differences between the two groups were considered significant at p < 0.05. Safety outcomes were analyzed by descriptive statistics and qualitative analysis for all emergent adverse events, measured after initial treatment to 4 weeks after treatment. In accordance with the protocol, primary analysis was performed using the ITT population, all secondary endpoints were summarized as descriptive statistics for the ITT population, and safety analyses were also performed on the ITT population.
Sample size was determined using the statistical program NQuery Advisor 3.0 (Statistical Solutions, Boston, MA, USA). A sample size of 257 was required for the treatment arm in each group to show a 12.3% increase from 47.7% (ritodrine response) to 59.7% (atosiban response) in tocolytic efficacy. This was the proportion of women who had not delivered at 7 days after treatment initiation and did not require alternative tocolytic therapy in a worldwide comparison of atosiban and beta-agonists in > 700 patients. 13 A level of significance of 5% (α = 0.05) and a power of 80% (β = 0.02) was used. The present study recruited a minimum of 40 patients, according to the suggestion of the Center for Drug Evaluation in Taiwan.
Results
A total of 45 patients diagnosed with preterm labor between 24 and 33 weeks gestation, confirmed by ultrasound, were enrolled and randomized to receive atosiban (n = 23) or ritodrine (n = 22). A trial flowchart is shown in the Figure. Among the ITT population, only 35 women completed treatment (20 in the atosiban group and 15 in the ritodrine group), and they were defined as the PP group. In the atosiban group, three patients were excluded because of the protocol requirement of the PP group. One patient delivered shortly after atosiban was administered (< 18 hours of atosiban treatment) and did not complete the study; the second patient discontinued the study after opting for cesarean section, and the third discontinued as a consequence of fetal distress (which had no apparent relation to the treatment). Therefore, a total of 20 patients remained in the PP group of the atosiban group.
In the ritodrine group, three patients were lost to follow-up after delivery but did complete the study (patient recruitment was around the period of SARS). Another four patients deviated from the requirements of the PP group because of a sub-standard ritodrine dosing regimen; therefore, 15 patients remained in the ritodrine PP group. Demographic characteristics (Table 1) of the atosiban and ritodrine groups were similar at admission (ITT population was used for analysis) in terms of their maternal age, obstetric history, height, weight and heart rate. The gestational age at recruitment (p = 0.043) and systolic blood pressure (p = 0.040) differed significantly between the two groups. There was also a difference in heart rate, although this was not statistically significant (p = 0.065). The pretreatment values of systolic blood pressure and heart rate fell within the normal ranges. There was no previous preterm delivery reported for any of the patients. Logistic regression analysis showed that none of these baseline demographic variables were associated significantly with the primary endpoint of the study (data not shown).
Tocolytic efficacy was accessed in terms of the proportion of women who remained undelivered and did not receive any alternative tocolytic therapy after 7 days of treatment (primary endpoint) ( Table 2 ). Using the ITT population for analysis, the rates of primary efficacy endpoint for atosiban and ritodrine groups were 78.3% (18/23) and 86.4% (19/22), respectively (p = 0.700). There was no significant difference observed between the two tocolytic treatments. Similarly, the proportion of patients who did not deliver within 2 days after treatment initiation and did not require alternative tocolytics was not shown to be significantly different for atosiban 82.6% (19/23) and ritodrine 86.4% (19/22) (p = 1.000; Table 1 ). When data were analyzed in the PP group, the number of women who remained undelivered and did not require alternative tocolytics at 2 and 7 days were similar for atosiban 90% (18/20) and ritodrine 100% (15/15) (p = 0.496). There was no difference observed in the primary efficacy endpoint for the atosiban and ritodrine Hyaline membrane disease is a respiratory disease of the newborn associated with prematurity. There was no occurrence of this condition in the atosiban group and only one recorded case (1/22) in the ritodrine group (p = 0.489; Table 3 ). Other secondary endpoints such as the frequency of uterine contractions were monitored at 0-2 days after therapy initiation. Overall, there were more changes in the uterine contraction rate observed at 0-18 hours and 0-2 days in the atosiban group compared with the ritodrine group, even though the differences were not statistically significant. There was no significant difference in maternal and perinatal outcomes, including infant birth weight, number of episodes of recurrent preterm labor, gestational age at delivery, number of days newborn infants spent in neonatal intensive care, number of days newborn infants spent on a ventilator, total number of days newborn infants spent in nursery, and proportion of patients with illnesses/handicaps (Table 3 ).
In view of the low number of subjects and outcome of adverse events, safety was evaluated descriptively by the occurrence of adverse events, except for the rate of tachycardia, which was compared statistically using Fisher's exact test. Overall, the occurrence of adverse events was not significantly different between the atosiban and ritodrine groups; three women from the atosiban group compared with four from the ritodrine group experienced adverse events (p = 0.700; Table 4 ). When the adverse events were analyzed in terms of their relationship with drug treatment (unknown, none, possible, probable or highly probable), there was no adverse event that had a highly probable relationship with atosiban treatment. However, there were three of five adverse events in the ritodrine group that had a highly probable relationship with drug treatment, and two had a probable relationship; all were patients with reported maternal tachycardia. When the adverse events were analyzed in terms of severity (mild, moderate or severe), no severe adverse event was reported throughout the study. All the adverse events were mild to moderate in severity and were similar between the two groups (Table 4 ). There was no recorded maternal or fetal death in either treatment group.
Adverse events in the two treatment groups were analyzed further by measuring the occurrence of tachycardia (heart rate > 120 bpm) or heart rate > 100 bpm. The occurrence of tachycardia was compared statistically using Fisher's exact test. Four patients (18.18%) in the ritodrine group experienced tachycardia at first treatment and none in the atosiban group, although the difference was not significant (Table 5 ). However, the proportion of patients with heart rate > 100 bpm at first treatment was significantly higher in the ritodrine group (20/22, 90 .9%) than in the atosiban group (3/22, 13.6%).
Discussion
The current study was performed in Taiwan on a population of patients similar in their ethnic background. There have been no previous randomized trials specifically designed to examine safety and efficacy of atosiban in the primary treatment of spontaneous preterm labor in this population. Our study provides further information and understanding of the treatment of preterm labor. Atosiban is the first oxytocin antagonist to be licensed for the specific treatment of preterm labor. It works by competing with oxytocin for the oxytocin receptors in the uterus, which then causes inhibition of the uterine contractions naturally brought on by oxytocin expression during labor. Clinical support from international studies as well as a recent Korean study has demonstrated that atosiban is superior when compared with beta-agonists, with respect to tocolytic efficacy and safety. 13, 14 As a result of the specific actions of atosiban on the oxytocin receptors in the uterus, maternal and fetal side effects are seldom observed. 1, 9, 13, 14 The present study compared the tocolytic efficacy of atosiban and beta-agonists in women with preterm labor who did not deliver and did not require alternative tocolytic therapy after 7 days. This endpoint is a composite outcome of efficacy and drug tolerability. Tocolytic efficacy for 2 days was also measured among other secondary and safety endpoints. There was no significant difference between atosiban and ritodrine in tocolytic efficacy for 2 or 7 days. This result differs from some previously reported studies of atosiban and various beta-agonists in the treatment of preterm labor, in which atosiban was shown to be significantly superior with respect to efficacy and safety. 13, 14 In a worldwide comparison of atosiban versus beta-agonists, the tocolytic efficacy was reported to be 59.7% in the atosiban group and 47.4% in the ritodrine group (p = 0.0003). 13 The difference in tocolytic efficacy in the present study may be explained partly by the small sample size compared with that in the previous study, which included > 700 preterm patients.
The actual percentage efficacy for atosiban and ritodrine was higher in our study compared with that in the worldwide study. This difference may be explained partly by the difference in ethnicity between the Taiwanese and worldwide studies. Many studies have shown that obstetric outcomes and gestational length vary by ethnicity, [15] [16] [17] [18] which may explain the variations obtained in studies with different ethnic backgrounds. The incidence of preterm delivery has been shown to be higher among Filipina women compared with Chinese and Japanese women in a study in the USA. 15 Further studies are required to confirm whether ethnicity really does influence tocolytic efficacy in preterm treatment in Taiwanese women. International clinical studies like the worldwide atosiban and beta-agonists study can be extended to include other Asian countries, to determine whether ethnic or cultural differences influence preterm treatment outcomes. One of the limitations of our study is the small sample size, which may explain the difference in tocolytic efficacy observed between the present and other reported studies. By performing larger randomized and international studies, we may overcome this limitation and gain more information on possible ethnic differences.
Past studies have shown that neonatal morbidity is related directly to gestational age at delivery. 18 One Cochrane review has shown that, although atosiban is associated with fewer maternal drug reactions that require treatment cessation, it increases the number of infants born under 1.5 kg, compared with beta-agonists. 19 There was no similar finding in our study. Our data showed that the mean gestational age for both treatment groups was similar at 37 weeks, and that both drugs were effective in delaying delivery, without severe maternal side effects and similar infant outcomes. The birth weight did not differ significantly between the two groups (atosiban vs. ritodrine: 2.9 ± 0.5 vs. 2.8 ± 0.4 kg). Overall, there was no severe or serious adverse events during the entire study, but more tachycardia (heart rate > 120 bpm) was observed in the ritodrine group.
Therefore, it can be concluded that the administration of ritodrine is associated with the adverse effect of tachycardia. Even more patients in the ritodrine group were diagnosed with tachycardia when the definition was changed to > 100 bpm. Tachycardia is a common cardiovascular side effect of beta-agonists in tocolytic studies, because of their physiological effect on β 1 adrenergic receptors; therefore, it is our intention to study the different safety profiles of the two drugs. Our results agree with previous studies in which significantly more treatment discontinuation and withdrawal was the consequence of maternal-fetal cardiovascular adverse effects from beta-agonist treatment. 1, 5, 13, 14 Beta-agonist treatment has also in the past been associated with other adverse events such as pulmonary edema and cardiac events. 20, 21 Although patients in the ritodrine group were at an earlier gestational age at admission and had higher systolic blood pressure compared with the atosiban group, further logistic regression analysis concluded that none of the demographic variables were associated with tocolytic efficacy or tachycardia and other maternal cardiovascular adverse effects (data not shown). The higher systolic blood pressure still fell within the normal acceptable range, thus, no bias was introduced that might have affected the interpretation of efficacy or safety results.
Overall, the present study shows that atosiban is an effective tocolytic agent. It is better tolerated when compared with beta-agonist treatment because of its high uterine specificity. Our results indicate that atosiban is a promising and safe treatment of preterm labor.
